Show simple item record

dc.contributor.authorAljohani, Badr A.
dc.date.accessioned2016-05-26T09:32:54Z
dc.date.available2016-05-26T09:32:54Z
dc.date.issued2016-09-11
dc.date.submitted2016-05-26T10:27:40.841Z
dc.identifier.citationAljohani, BA. 2016. Pharmaceutical Bioequivalence Studies: Ensuring Safety, Effectiveness and High Quality. Queen Mary University of Londonen_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/12527
dc.description.abstractPoor quality medicines are a global problem affecting both developed and developing countries. Governments and the health authorities are focusing on the spread of counterfeit medicines, as it is a threat to patients and funds criminal activities. Recently questions have been raised about using generic substitutes, especially for Narrow Therapeutic Index Drugs (NTIDs), such as ciclosporin. In-vitro dissolution testing was undertaken to identify differences in dissolution performance between branded and generic ciclosporin capsules. Dissolution testing of the capsules was carried out according to the USP guidelines. According to the USP not less than 80% of the labelled amount of ciclosporin should dissolve in 90 min. The samples were analysed using a HPLC method. Two ciclosporin generic products showed less than the minimum percentage of labelled amount < 80%. Statistical analysis showed significant differences (p<0.0001) of the mean percentage content between brand and generic. Investigations were carried out to detect impurities in ciclosporin capsules using LC-MS. Concentrations of inactive ingredients such as sorbitol were variable between capsules. One from South America, manufactured in central Asia, showed contamination with a plant product (Zizyphine A). the synthetic intermediate (Delcorine) was found to be more than 1000 fold higher in the generic product compared to reference capsules (p<0.001). In 2013, the FDA warned of the possible fatal effect of azithromycin. LC-MS quantification for azithromycin tablets were carried out in order to quantify azithromycin content in different products. A bioequivalence study in man, confirmed that generic (Mazit) capsules were bioequivalent with brand (Zithromax™) capsules. Based on the results presented in this thesis, HPLC and LC-MS proved suitable approaches for analysis of drugs and their unknown impurities in brand, generic and counterfeit medicines. Some ciclosporin preparations did not contain the mass labelled. Therefore, switching between branded and generic ciclosporin may lead to undesirable effect.
dc.language.isoenen_US
dc.publisherQueen Mary University of Londonen_US
dc.subjectNarrow Therapeutic Index Drugsen_US
dc.subjectCiclosporinen_US
dc.subjectSubstandard and counterfeit medicinesen_US
dc.titlePharmaceutical Bioequivalence Studies: Ensuring Safety, Effectiveness and High Qualityen_US
dc.typeThesisen_US
dc.rights.holderThe copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author


Files in this item

Thumbnail

This item appears in the following Collection(s)

  • Theses [2958]
    Theses Awarded by Queen Mary University of London

Show simple item record